Clinical Observations of Exenatide Treatment
نویسندگان
چکیده
منابع مشابه
Clinical Observations of Exenatide Treatment
Controlled clinical trials have demonstrated the effectiveness of exenatide in reducing glucose and weight (1– 4). We herein report our initial clinical experience. Clinic charts of the first 200 patients consecutively treated were retrospectively analyzed. Of these patients, 22% were lost to follow-up, noncompliant, or chose not to continue for reasons other than side effects. Thirteen percent...
متن کاملClinical observations of exenatide treatment.
Controlled clinical trials have demonstrated the effectiveness of exenatide in reducing glucose and weight (1– 4). We herein report our initial clinical experience. Clinic charts of the first 200 patients consecutively treated were retrospectively analyzed. Of these patients, 22% were lost to follow-up, noncompliant, or chose not to continue for reasons other than side effects. Thirteen percent...
متن کاملThe variable weight effect of exenatide treatment.
Corresponding Author: Allen B. King, M.D., Diabetes Care Center, 1260 S. Main, Salinas, CA 93901; email address [email protected] Exenatide, a glucagon-like peptide-1 agonist, has enjoyed popularity with treating physicians because it dramatically reduces postmeal glucose (at least early in diabetes), increases β cell mass (at least in vitro and in rodents), and reduces weight. Some ...
متن کاملIs Exenatide a Treatment for Parkinson's Disease?
There is growing interest in the use of glucagon-like peptide-1 agonists as treatments for Parkinson's disease following the recent publication of the results of the Exenatide-PD trial. In this randomized, double-blind, placebo controlled trial, patients with moderate stage Parkinson's disease treated with once-weekly subcutaneous injections of exenatide 2 mg (Bydureon) for 48 weeks, had a 3.5-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Care
سال: 2006
ISSN: 0149-5992,1935-5548
DOI: 10.2337/dc06-0864